A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia

Trial Profile

A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs GMI 1271 (Primary) ; Cytarabine; Etoposide; Idarubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 25 Jun 2017 Results (n=47)presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results (n=17) of Arm C, presented at the 22nd Congress of the European Haematology Association
    • 05 Jun 2017 Results from this trial published in a GlycoMimetics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top